Posts Tagged ‘Caroline Popper’



#BIO2011: After the Party is Over

June 30th, 2011
Posted by

For the thousands of  life science industry representatives who attend the Biotechnology Industry Organization Annual Convention each year, the last few days have been similar to a favorite holiday: exciting, long-awaited, and too quickly over. As we wrap up our #BIO2011 experience and say good-bye to Washington, DC, I took a few moments to look back on many inspiring networking and learning opportunities only available at this kind of international event.
 
Within the span of a few days, my colleague Caroline Popper and I have been able to meet with clients, colleagues and new contacts from states such as Michigan, California, Texas, and Massachusetts.  Furthermore, a large exhibit hall showcasing different regions of the world’s biotech industry has been an extraordinary venue to network with international visitors. I traveled to DC from my office in Toronto, and was able to meet with life science representatives from Australia, New Zealand, Spain, and Italy, sharing with them ideas and guidance for how to establish a presence in North America.
  Read the rest of this entry »

Tags: , , , ,
Posted in Events | Comments Off on #BIO2011: After the Party is Over





This Is Not Your Grandfather’s Big Diagnostics

February 7th, 2011
Posted by

Danaher Corporation (NYSE:DHR) announced today (see San Francisco Chronicle story here) that it has entered into an agreement with Beckman Coulter, Inc. (NYSE: BEC) to acquire Beckman for approximately $6.8 billion. When the acquisition is complete, Beckman will become part of Danaher’s Life Sciences and Diagnostics business segment.
 
This is yet another example of the diagnostics landscape’s rapid upheaval in which different players will clearly be dominating and leading the industry.
 
The diagnostics industry shake up is in full swing: As we wrote recently, sequencing technology (one critical part of the Dx space) is changing at an earth-shattering speed and today’s announcement is evidence of what is happening on the market level. Need more evidence? Check out this post by Xconomy’s Luke Timmerman on “diagnostics warming up.”
  Read the rest of this entry »

Tags: , , , , , , ,
Posted in Our Views | Comments Off on This Is Not Your Grandfather’s Big Diagnostics





A Year in Books – These are a few of our favorite reads…

December 26th, 2010
Posted by

The Popper and Company team invests a great deal of time conducting literature reviews of scientific and medical journals and trade publications, but we also enjoy digging our heels in for varied reading experiences offered by great authors and great minds.
 
Following is a list of some of the best and most memorable books we’ve read this year. This list clearly provides a sense of our eclectic team and offers you an understanding of the broad perspective we bring to your life science business opportunities.
 

Books are the quietest and most constant of friends; they are the most accessible and wisest of counselors, and the most patient of teachers. -- Charles W. Eliot

  Read the rest of this entry »

Tags: , , , , , ,
Posted in Our Views | Comments Off on A Year in Books – These are a few of our favorite reads…





Increasing Drug & Device Complexity: Impact on the U.S. Regulatory Review Process

December 8th, 2010
Posted by

Last week, PwC issued a report entitled “Improving America’s Health V—A survey of the working relations between the life sciences industry and FDA.” In a release announcing the report, PwC explained,  “Growing public demand for increased medical device and drug safety, as well as the need to develop medical products faster, is complicating the current regulatory approval process and relationship between the life sciences industry and its chief regulator, the U.S. Food and Drug Administration.”
 
I certainly agree that the FDA as a resource is constrained. This is a somewhat predictable predicament, however, in that products being considered for marketing approval as well as those currently regulated by the FDA are more complex today than ever before. As complexity rises, the agency clearly needs more resources and augmentation in specific skill areas, such as informatics and genomics.
  Read the rest of this entry »

Tags: , , , ,
Posted in Our Views | Comments Off on Increasing Drug & Device Complexity: Impact on the U.S. Regulatory Review Process





Observations from the World Circulating Tumor Cell (CTC) Summit

December 6th, 2010
Posted by

The World Circulating Tumor Cell Summit occurred in Boston, Massachusetts from November 30 to December 1, 2010. My colleague Shane Climie and I attended, and here we share the top 10 ideas we took away from this important meeting, which focused on exploring the near-term commercial potential of many of the exciting new CTC technologies. Presenters and attendees at the meeting also discussed how CTCs might be utilized both in clinical trials and in clinical practice.
 
While the research community is still seeking to determine exactly what a CTC is, efforts to detect, isolate and characterize CTCs continue to increase.
 
Our Top 10 Takeaways:
  Read the rest of this entry »

Tags: , , , ,
Posted in Our Views | Comments Off on Observations from the World Circulating Tumor Cell (CTC) Summit